BioCentury
ARTICLE | Company News

Cumberland, Fresenius, InnoPharma, Perrigo Co. sales and marketing update

January 14, 2013 8:00 AM UTC

Perrigo and Fresenius' Fresenius Kabi USA LLC subsidiary each launched a generic version of Cumberland's acetaminophen poisoning drug Acetadote acetylcysteine injection in the U.S. Perrigo's version is an authorized generic.

Last November, Cumberland agreed to supply the authorized generic to Perrigo should Cumberland elect to launch an authorized generic. The agreement was part of settled litigation brought against Perrigo alleging that the defendant's ANDA submission for a generic version of Acetadote infringed Cumberland's U.S. Patent No. 8,148,356. As part of the settlement, Perrigo will share revenue with Cumberland. Cumberland reported $26.9 million in Acetadote sales for the first nine months of 2012 (see BioCentury, Nov. 19, 2012). ...